Press release
Dulaglutide Market Size, Emerging Trends, Growth Rate, Business Opportunities And Forecast To 2033
The Business Research Company recently released a comprehensive report on the Global Dulaglutide Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18338&type=smp
According to The Business Research Company's, The dulaglutide market size has grown strongly in recent years. It will grow from $3.87 billion in 2023 to $4.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the increasing prevalence of type 2 diabetes, increasing utilization, increasing research and development investments, increased focus on chronic diseases, and growth in personalized medicine.
The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing clinical trials, rising obesity rates, rising aging population, growing telemedicine services, growing endocrinology clinics, and growing use of electronic health records. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, digital health platforms, and mobile health apps.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/dulaglutide-global-market-report
Market Drivers and Trends:
The increasing prevalence of type 2 diabetes is expected to propel the growth of the dulaglutide market going forward. Type 2 diabetes is a chronic condition where the body becomes resistant to insulin or doesn't produce enough insulin, leading to elevated blood sugar levels. The increase in type 2 diabetes is due to rising rates of obesity, poor diets, and sedentary lifestyles. Dulaglutide helps manage type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in response to food intake, which lowers blood sugar levels. For instance, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults aged 20 to 79 in 2021, with that figure anticipated to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of type 2 diabetes is driving the growth of the dulaglutide market.
Major companies operating in the dulaglutide market are focused on developing innovative products, such as anti-diabetic drugs, to meet the increasing demand for effective treatments for managing diabetes mellitus. Anti-diabetic drugs are medications that manage and treat diabetes mellitus by regulating blood sugar levels through mechanisms like increasing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive tract. For instance, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched the first biosimilar of the anti-diabetic drug Liraglutide in India under the brand name Lirafit. This move signifies Glenmark's strategic entry into the biosimilar market for anti-diabetic drugs, aimed at providing patients with a more affordable treatment option. The biosimilar is expected to maintain efficacy and safety profiles comparable to the original drug, meeting stringent regulatory standards.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark
Dulaglutide Market 2024 Key Insights:
• The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%.
• The Rising Prevalence Of Type 2 Diabetes Fuels Growth In The Dulaglutide Market
• Glenmark's Launch Of Lirafit Biosimilar Expands Access To Anti-Diabetic Treatments
• North America was the largest region in the dulaglutide market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=18338&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (https://www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample of Our Research Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=18338&type=smp
According to The Business Research Company's, The dulaglutide market size has grown strongly in recent years. It will grow from $3.87 billion in 2023 to $4.17 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to the increasing prevalence of type 2 diabetes, increasing utilization, increasing research and development investments, increased focus on chronic diseases, and growth in personalized medicine.
The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing clinical trials, rising obesity rates, rising aging population, growing telemedicine services, growing endocrinology clinics, and growing use of electronic health records. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, digital health platforms, and mobile health apps.
Get The Complete Scope Of The Report @
https://www.thebusinessresearchcompany.com/report/dulaglutide-global-market-report
Market Drivers and Trends:
The increasing prevalence of type 2 diabetes is expected to propel the growth of the dulaglutide market going forward. Type 2 diabetes is a chronic condition where the body becomes resistant to insulin or doesn't produce enough insulin, leading to elevated blood sugar levels. The increase in type 2 diabetes is due to rising rates of obesity, poor diets, and sedentary lifestyles. Dulaglutide helps manage type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in response to food intake, which lowers blood sugar levels. For instance, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults aged 20 to 79 in 2021, with that figure anticipated to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing prevalence of type 2 diabetes is driving the growth of the dulaglutide market.
Major companies operating in the dulaglutide market are focused on developing innovative products, such as anti-diabetic drugs, to meet the increasing demand for effective treatments for managing diabetes mellitus. Anti-diabetic drugs are medications that manage and treat diabetes mellitus by regulating blood sugar levels through mechanisms like increasing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive tract. For instance, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched the first biosimilar of the anti-diabetic drug Liraglutide in India under the brand name Lirafit. This move signifies Glenmark's strategic entry into the biosimilar market for anti-diabetic drugs, aimed at providing patients with a more affordable treatment option. The biosimilar is expected to maintain efficacy and safety profiles comparable to the original drug, meeting stringent regulatory standards.
Key Benefits for Stakeholders:
• Comprehensive Market Insights: Stakeholders gain access to detailed market statistics, trends, and analyses that help them understand the current and future landscape of their industry.
• Informed Decision-Making: The reports provide crucial data that support strategic decisions, reducing risks and enhancing business planning.
• Competitive Advantage: With in-depth competitor analysis and market share information, stakeholders can identify opportunities to outperform their competition.
• Tailored Solutions: The Business Research Company offers customized reports that address specific needs, ensuring stakeholders receive relevant and actionable insights.
• Global Perspective: The reports cover various regions and markets, providing a broad view that helps stakeholders expand and operate successfully on a global scale.
Major Key Players of the Market:
Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark
Dulaglutide Market 2024 Key Insights:
• The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $5.66 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%.
• The Rising Prevalence Of Type 2 Diabetes Fuels Growth In The Dulaglutide Market
• Glenmark's Launch Of Lirafit Biosimilar Expands Access To Anti-Diabetic Treatments
• North America was the largest region in the dulaglutide market in 2023
We Offer Customized Report, Click @
https://www.thebusinessresearchcompany.com/customise?id=18338&type=smp
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company (https://www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage
to this press release on woodPRI. woodPRI disclaims liability for any content contained in
this release.
Recommend
/newsMicroencapsulation Market Deep Analysis on Key Players - Dow Corning, Encapsys, Syngenta Crop Protection, Evonik Industries, 3M and Bayer
Market Study Report Adds Global Microencapsulation Market Size, Status and Forecast 2024 added to its database. The report provides key statistics on the current state of the industry and other analytical data to understand the market.
Extensive research is required for choosing the appropriate cor...
/newsGermany Airbag Market Size 2023: Global Share, Industry And Report Analysis By 2030 | Hyundai Mobis Co., Ltd. Key Safety Systems, Inc. Robert Bosch GmbH
Germany airbag market is expected to grow at a CAGR of around 6% during the forecast period. Germany Airbag Market research report refers to gathering and analyzing significant market data serve as best medium for various industry players to launch novel product or service. It is vital for key firms...
/newsSecurities Brokerages And Stock Exchanges Market Outlook 2021: Big Things are Happening
A new intelligence report released by HTF MI with title "Global Securities Brokerages And Stock Exchanges Market Survey & Outlook" is designed covering micro level of analysis by Insurers and key business segments, offerings and sales channels. The Global Securities Brokerages And Stock Exchange...
/newsRenewable Chemicals Market Emerging Trends and Competitive Landscape Forecast to 2028
The renewable chemicals market was valued at US$ 80,566.30 million in 2021 and is projected to reach US$ 1,76,750.76 million by 2028 it is expected to grow at a CAGR of 11.9% from 2021 to 2028. The research report focuses on the current market trends, opportunities, future potential of the market, a...
/newsHow Coronavirus is Impacting Cold Brew Coffee, Global Market Volume Analysis, Size, Share and Key Trends 2020-2026
"Market Latest Research Report 2020:
Los Angles United States, February 2020: The Cold Brew Coffee market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Research's lates...
/newsCorporate E-Learning Market - Global Industry Size, Share, Key Players Analysis that are Infor, SkillSoft Corporation, Adrenna, CERTPOINT Systems and others with Regional Forecast to 2022
Overview:
E-Learning is used to enhance the learning procedures for newer job requirements and to make employees sound about the internal and external changes in the market and respective organizations. This method has created considerable differences in the ways of training and developing employee...
